There is an urgent need, therefore, to identify well-tolerated, orally available compounds
that target the NMDA receptor as a novel treatment approach for TRD. The current project aims
to test the safety, tolerability and efficacy of Nuedexta - containing the NMDA antagonist
dextromethorphan.